The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer

Trial ID # Retrospective Study: Cyc + Bev
Phase II
Drug Class Angiogenesis Inhibitors: VEGF
Drug Name Bevacizumab
Alternate Drug Names immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin
Drugs in Trial Bevacizumab, Cyclophosphamide
Eligible Participant

Platinum-resistant ovarian cancer

Patients Enrolled

66; median 6.5 prior therapies (3-16)

Therapy Setting

Recurrence

Study Design

Open-Label, Non-randomized

Endpoints

ORR, DCR, PFS, OS, evaluated per RECIST or CA125

Efficacy

ORR: 42.4% (7CR, 21PR, n=66)
DCR: 65.1% (7CR, 21PR, 15SD, n=66)
PFS: 3 months (0-14)
OS: 12 months (2-56)

Clinically Significant Adverse Events

Serious AE: one bowel perforation
Grade 3-4 AE: two patients with grade 4 hypertension with headache requiring presentation to the emergency room

Conclusion

Cyclophosphamide+bevacizumab is an effective, well-tolerated combination in heavily pretreated patients

Reference

Barber EL et al. The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer. J Gynecol Oncol (2013) 24(3): 258-64
https://www.ncbi.nlm.nih.gov/pubmed/23875076